Overview
This study will assess the safety and effectiveness of Maviret (Glecaprevir plus Pibrentasvir (GLE/PIB)) in adolescent participants diagnosed with chronic hepatitis C (CHC) in a real world setting across clinical practice in Japan.
Eligibility
Inclusion Criteria:
- Chronic Hepatitis C Virus (HCV) infection treated in daily practice with Maviret
- Enrolled after Maviret treatment begins
- Prior treatment with Maviret
Exclusion Criteria:
None